Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytochrome c pseudogene 26 (CYCSP26, also known as HCP26) is one of 49 reported cytochrome c (cyc) pseudogenes in the human genome[2][3]. Pseudogenes such as CYCSP26 originate from genomic duplication or retrotransposition events and are typically characterized by the absence of introns, truncating mutations, disablements in coding regions (such as frame shifts or premature stop codons), and lack of expression. CYCSP26 does not code for a functional protein, is not involved in cellular metabolism or signaling, and plays no known biological or pathological role. None of the cytochrome c pseudogenes, including CYCSP26, are expressed or implicated as therapeutic targets[2][3].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytochrome c pseudogene 26 (CYCSP26).